95 completed, 20 terminated, 19 unknown, 11 recruiting. 89 Phase 2, 29 Phase 3, 28 Phase 1, 13 Phase 4, 4 Not applicable.
Follow eltrombopag: new trials by email Literature Review of eltrombopag trials Research Report on eltrombopag
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids. Ianalumab, Eltrombopag - Primary Immune Thrombocytopenia (ITP) | Phase 2 | Not yet recruiting | Novartis Pharmaceuticals | 36 | 2027-02-08 | 2026-06-25 |
| A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) ianalumab, thrombopoietin receptor agonist (TPO-RA) - Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES) | Phase 2 | Recruiting | Novartis Pharmaceuticals | 164 | 2026-08-04 | 2026-10-22 |
| Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP Eltrombopag - Immune Thrombocytopenia | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 40 | 2026-07-10 | 2026-07-07 |
| TPO-RA Plus Baricitinib vs. TPO-RA for ITP Baricitinib, TPO-RA - ITP - Immune Thrombocytopenia | Phase 2 | Not yet recruiting | Peking University People's Hospital | 100 | 2026-07-01 | 2026-06-25 |
| Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia standard-dose methylprednisolone/prednisone., thrombopoietin receptor agonist(TPO-RA), including but not limited to hetrombopag or eltrombopag., rituximab. - ITP - Immune Thrombocytopenia | Phase 4 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 38 | 2026-06-22 | 2026-08-26 |
| Observational Study on Eltrombopag in Hypocellular Myelodysplastic Neoplasms Eltrombopag (ELT) - Myelodysplastic Neoplasm, Myelodysplastic Syndrome | Active not recruiting | Fondazione Italiana Sindromi Mielodisplastiche-ETS | 100 | 2026-05-01 | 2026-09-17 | |
| CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAA Cyclosporine (CsA), thrombopoietin receptor agonist (TPO-RA), Romiplostim N01 - Severe Aplastic Anemia (SAA), Transfusion-dependent Non-severe Aplastic Anemia | Phase 2 | Not yet recruiting | Peking Union Medical College Hospital | 43 | 2026-04-01 | 2026-04-30 |
| Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP Eltrombopag, Placebo - Primary Immune Thrombocytopenia (ITP) | Phase 4 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 150 | 2025-12-01 | 2025-09-24 |
| Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease Busulfan, Tocilizumab, Eltrombopag - Chronic Granulomatous Disease (CGD) | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2025-09-10 | 2026-09-08 |
| Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura Eltrombopag - ITP - Immune Thrombocytopenia | Not applicable | Recruiting | Sohag University | 100 | 2025-07-14 | 2025-07-30 |
| Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations Eltrombopag (EPAG) - Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | Phase 2 | Suspended | Abhay Singh, MD MPH | 25 | 2025-06-17 | 2026-10-09 |
| Bioequivalence Study of Revolade® Eltrombopag 50 mg Revolade®, Eltrombopag (EPAG) - Healthy, Healthy Donors | Phase 4 | Active not recruiting | Centro de Atencion e Investigacion Medica | 30 | 2025-06-01 | 2025-06-19 |
| Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia. Eltrombopag 25 MG, Prednisolone - Primary Immune Thrombocytopenia | Phase 1 / Phase 2 | Recruiting | Renata PLC | 100 | 2025-02-07 | 2025-02-18 |
| Ripertamab Plus Eltrombopag vs. Eltrombopag in ITP Patients Post-Steroid Failure Ripertamab/Eltrombopag, Eltrombopag - ITP - Immune Thrombocytopenia | Not applicable | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 78 | 2025-02-01 | 2025-01-24 |
| REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2 Ruxolitinib (JAKAVI®), Eltrombopag (Revolade®) - Poor Graft Function, Aplastic Anemia Idiopathic | Phase 1 / Phase 2 | Not yet recruiting | Melbourne Health | 20 | 2024-10-30 | 2024-09-23 |
| High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly Ruxolitinib, Allogeneic Stem Cell Transplantation, Levetiracetam - Splenomegaly, Myelofibrosis | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2024-10-01 | 2026-09-16 |
| Revolade Tablets Specified Drug-use Survey eltrombopag - Aplastic Anemia | Recruiting | Novartis Pharmaceuticals | 10 | 2024-07-17 | 2026-02-19 | |
| Outcomes in Bone Marrow Aplasia. Eltrombopag - Aplastic Anemia Idiopathic | Phase 3 | Not yet recruiting | Assiut University | 3 | 2024-07-01 | 2024-07-10 |
| The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP Hydroxychloroquine Oral Tablet, Eltrombopag - Immune Thrombocytopenia With Positive ANA Antibodies | Not applicable | Recruiting | Yunfeng Cheng | 126 | 2024-07-01 | 2024-06-28 |
| Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura eltrombopag and romiplastim - ITP - Immune Thrombocytopenia | Not yet recruiting | Assiut University | 100 | 2023-12-01 | 2023-11-18 |
Showing 20 of 169. Sign in to see all of them.
Thrombocytopenia (60) · Purpura, Thrombocytopenic, Idiopathic (53) · Anemia, Aplastic (22) · Purpura (14) · Jacobs syndrome (13) · Myelodysplastic Syndromes (13) · Hepatitis C (11) · Leukemia, Myeloid, Acute (11) · Autoimmune Diseases (7) · Leukemia (7) · Hemorrhage (6) · Blood Platelet Disorders (4) · Hepatitis C, Chronic (4) · Leukemia, Myelomonocytic, Chronic (4) · Pancytopenia (4)
GlaxoSmithKline (32) · Novartis Pharmaceuticals (23) · National Heart, Lung, and Blood Institute (NHLBI) (8) · M.D. Anderson Cancer Center (7) · Institute of Hematology & Blood Diseases Hospital, China (6) · Peking University People's Hospital (6) · Assiut University (4) · Weill Medical College of Cornell University (4) · Gruppo Italiano Malattie EMatologiche dell'Adulto (3) · The First Affiliated Hospital of Soochow University (3) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (3) · Associazione Qol-one (2) · Dana-Farber Cancer Institute (2) · European Society for Blood and Marrow Transplantation (2) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (2)
United States (66) · China (29) · Italy (24) · France (21) · Germany (19) · Russia (18) · Spain (18) · Taiwan (14) · United Kingdom (14) · Canada (13) · Hong Kong (13) · Poland (13) · South Korea (13) · Australia (11) · Greece (11)
Cynthia E Dunbar, M.D. (3) · Xiaohui Zhang, MD (3) · Courtney DiNardo, MD (2) · Moshe Yeshurun, MD (2) · Nancy Berliner, MD (2) · Neal S Young, M.D. (2) · Uday Popat, MD (2) · Abhay Singh, MD, MPH (1) · Alessandro Pecci, M.D. (1) · Alexandra Schifferli, Dr. med. (1) · Alexei Maschan (1) · Amanda Grimes, MD (1) · Amit K Verma (1)
PMID 19005182, PMID 24802773, PMID 19846889, PMID 21533818, PMID 22117897, PMID 22409309, PMID 23492914, PMID 24126097, PMID 25777337, PMID 26173631, PMID 26231455, PMID 26688484, PMID 29419434, PMID 29536526, PMID 29958797, PMID 30992268, PMID 34452956, PMID 11919310, PMID 12359731, PMID 15661401, PMID 17452226, PMID 18046028, PMID 19231632, PMID 19446149, PMID 20148887, PMID 20671616, PMID 20844233, PMID 22054810, PMID 22762314, PMID 2279341, PMID 22913681, PMID 23169778, PMID 23361904, PMID 23389750, PMID 23452139, PMID 23470153, PMID 23497336, PMID 23556122, PMID 23896965, PMID 24120380, PMID 24254965, PMID 24345753, PMID 24674813, PMID 25132654, PMID 25830126, PMID 26224646, PMID 26354756, PMID 26477577, PMID 2665875, PMID 26709028
2018 (3), 2014 (2), 2015 (2), 2017 (2), 2016 (1), 2019 (1), P30CA013330 (1)